Crosstalk between adenosine receptor (A2A isoform) and ERα mediates ethanol action in MCF-7 breast cancer cells

Flament,

doi:10.3892/or_00000311

Cited by 19 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have also shown an anti-tumor action of A 2A AR in A375 melanoma (Merighi et al, 2002) and human colon cancer cells (Yasuda et al, 2009), the latter mediated by activation of caspases. In contrast, the A 2A AR promotes growth of breast cancer MCF-7 breast cancer cells (Etique et al, 2009) and increases angiogenesis by inducing VEGF expression (Montesinos et al, 2002). These studies suggest that A 2A AR antagonists could be useful in cancer by blocking angiogenesis.…”

Section: Adenosine Receptors In Cancermentioning

confidence: 96%

Breakthroughs in Melanoma Research

Tanaka¹

2011

View full text Add to dashboard Cite

is a board certified plastic surgeon who is dedicated to his patients as well as an enthusiastic researcher. He received his MD from Shinshu University School of Medicine in 2000., followed by a Ph.D. from Shinshu University Graduate School of Medicine in 2010. In addition to being a clinical assistant professor at the department of plastic and reconstructive surgery of Shinshu University School of Medicine, he is also the founder of the Clinica Tanaka Plastic and Reconstructive Surgery and Anti-aging Center, and the Society for Near-infrared rays Research. Dr. Yohei Tanaka enthusiastically performs various researches at Shinshu University, his own clinic, and his laboratory. He now specializes in blepharoplasty, filler injection, and the biological investigation of near-infrared radiation.

show abstract

Section: Adenosine Receptors In Cancermentioning

confidence: 96%

Breakthroughs in Melanoma Research

Tanaka¹

2011

View full text Add to dashboard Cite

show abstract

“…A2AR is highly expressed in certain tumors, such as head and neck squamous cell carcinoma and breast cancer. This high expression is significantly associated with increased tumor volume, advanced pathological grade, and diminished overall survival 97–99 . The previous studies have shown that blocking A2AR in mice can enhance the immune response against tumors and inhibit tumor growth and metastasis 100 .…”

Section: Purines and Purinergic Receptors In Tumorsmentioning

confidence: 99%

“…This high expression is significantly associated with increased tumor volume, advanced pathological grade, and diminished overall survival. 97 , 98 , 99 The previous studies have shown that blocking A2AR in mice can enhance the immune response against tumors and inhibit tumor growth and metastasis. 100 In the investigation of adenosine receptors’ role in cancer cells, A2BR and A2BR have emerged as two extensively studied receptors (Tables 2 and 3 ).…”

Section: Purines and Purinergic Receptors In Tumorsmentioning

confidence: 99%

Purine and purinergic receptors in health and disease

Ai,

Wang,

Liu

et al. 2023

MedComm

View full text Add to dashboard Cite

Purines and purinergic receptors are widely distributed throughout the human body. Purine molecules within cells play crucial roles in regulating energy metabolism and other cellular processes, while extracellular purines transmit signals through specific purinergic receptors. The ubiquitous purinergic signaling maintains normal neural excitability, digestion and absorption, respiratory movement, and other complex physiological activities, and participates in cell proliferation, differentiation, migration, and death. Pathological dysregulation of purinergic signaling can result in the development of various diseases, including neurodegeneration, inflammatory reactions, and malignant tumors. The dysregulation or dysfunction of purines and purinergic receptors has been demonstrated to be closely associated with tumor progression. Compared with other subtypes of purinergic receptors, the P2X7 receptor (P2X7R) exhibits distinct characteristics (i.e., a low affinity for ATP, dual functionality upon activation, the mediation of ion channels, and nonselective pores formation) and is considered a promising target for antitumor therapy, particularly in patients with poor response to immunotherapy This review summarizes the physiological and pathological significance of purinergic signaling and purinergic receptors, analyzes their complex relationship with tumors, and proposes potential antitumor immunotherapy strategies from tumor P2X7R inhibition, tumor P2X7R overactivation, and host P2X7R activation. This review provides a reference for clinical immunotherapy and mechanism investigation.

show abstract

“…The activation of ADORA on tumor cells regulates cell proliferation, apoptosis, cytoprotection and migration [199,200]. In particular, the adenosine A2A receptor (ADORA2a) has been found to be overexpressed in HNSCC [201,202] and in several melanoma and breast cancer cell lines [203][204][205]. The ADORA2a downstream pathway inhibits JAK/STAT signaling, either by preventing phosphorylation or inducing the proteasomal degradation of STAT proteins [206].…”

Section: Cd38 and Adenosine Receptor Activationmentioning

confidence: 99%

IFN-γ and CD38 in Hyperprogressive Cancer Development

Angelicola

Ruzzi

Landuzzi

et al. 2021

Cancers

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) improve the survival of patients with multiple types of cancer. However, low response rates and atypical responses limit their success in clinical applications. The paradoxical acceleration of tumor growth after treatment, defined as hyperprogressive disease (HPD), is the most difficult problem facing clinicians and patients alike. The mechanisms that underlie hyperprogression (HP) are still unclear and controversial, although different factors are associated with the phenomenon. In this review, we propose two factors that have not yet been demonstrated to be directly associated with HP, but upon which it is important to focus attention. IFN-γ is a key cytokine in antitumor response and its levels increase during ICI therapy, whereas CD38 is an alternative immune checkpoint that is involved in immunosuppressive responses. As both factors are associated with resistance to ICI therapy, we have discussed their possible involvement in HPD with the conclusion that IFN-γ may contribute to HP onset through the activation of the inflammasome pathway, immunosuppressive enzyme IDO1 and activation-induced cell death (AICD) in effector T cells, while the role of CD38 in HP may be associated with the activation of adenosine receptors, hypoxia pathways and AICD-dependent T-cell depletion.

show abstract

Crosstalk between adenosine receptor (A2A isoform) and ERα mediates ethanol action in MCF-7 breast cancer cells

Cited by 19 publications

References 25 publications

Breakthroughs in Melanoma Research

Breakthroughs in Melanoma Research

Purine and purinergic receptors in health and disease

IFN-γ and CD38 in Hyperprogressive Cancer Development

Contact Info

Product

Resources

About